Effect of Prophylaxis on Fungal Infection and Costs for High-Risk Liver Transplant Recipients
Authors:
Open Access
- 28 November 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Liver Transplantation
- Vol. 13 (12) , 1743-1750
Abstract
We sought to determine whether the prophylactic use of amphotericin B products (conventional amphotericin B and liposomal amphotericin B) reduces the incidence of fungal infections in high-risk liver transplant recipients, and if so, whether this lowers the cost of care. The study sample comprised 232 adult orthotopic liver transplants performed from 1994 to 2005 at a single center for patients classified as being at high risk for fungal infections. High-risk patients who received transplants with a prophylaxis regimen of amphotericin B (n = 58 transplants) were compared with high-risk patients who received no prophylaxis (n = 174 transplants). Fungal infections occurred in 3 transplants (5.17%) of those who received amphotericin B and 28 transplants (16.09%) in those without prophylaxis ( P = 0.0432). Regression models were used to analyze fungal infection and costs for the 232 high-risk transplants. Failure to offer prophylaxis conferred a 4-fold greater risk of fungal infection ( P = 0.046) compared with those who received amphotericin B. A fungal infection in a high-risk recipient increased mean costs by 46.48%. The indirect effect of prophylaxis (operating through infection reduction) is estimated to reduce overall costs in high-risk patients by 8.73%. Liver Transpl 13: 1743–1750, 2007. © 2007 AASLD.Keywords
This publication has 26 references indexed in Scilit:
- Who Pays for Biliary Complications Following Liver Transplant? A Business Case for Quality ImprovementAmerican Journal of Transplantation, 2006
- Impact of Recipient MELD Score on Resource UtilizationAmerican Journal of Transplantation, 2006
- Low‐dose amphotericin for prevention of serious fungal infection following liver transplantationTransplant Infectious Disease, 2005
- Optimal prophylactic dosage and disposition of micafungin in living donor liver recipientsClinical Transplantation, 2004
- Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patientsJournal of Antimicrobial Chemotherapy, 2003
- Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled studyTransplant International, 2002
- Targeted prophylaxis with amphotericin B lipid complex in liver transplantationLiver Transplantation, 2000
- RISK FACTORS OF INVASIVE CANDIDA AND NON-CANDIDA FUNGAL INFECTIONS AFTER LIVER TRANSPLANTATION1Transplantation, 1996
- Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipientsMycoses, 1996
- Factors Associated with the Development of Candidemia and Candidemia-Related Death Among Liver Transplant RecipientsAnnals of Surgery, 1996